Cohance Lifesciences (formerly Suven Pharma) will invest $10 million in NJ Bio, US, for a cGMP bioconjugation suite to produce ADCs, and ₹23 crore in Hyderabad for a cGMP oligonucleotide facility. In FY25, revenue grew 9.1% YoY to ₹2,610.3 crore, EBITDA margin was 31.3%, while PAT fell 4.8% to ₹546.3 crore. Shares rose 4% to ₹985.75.